Meeting
2022 ASCO Gastrointestinal Cancers Symposium
A randomized phase III trial of mFOLFOX7 or CapeOX plus bevacizumab versus 5-FU/l-LV or capecitabine plus bevacizumab as initial therapy in elderly patients with metastatic colorectal cancer: JCOG1018 study (RESPECT).
Presenter
Tetsuya Hamaguchi, MD, PhD
Department of Medical Oncology, Saitama Medical University International Medical Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Oral Abstract Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
UMIN000008866
DOI
10.1200/JCO.2022.40.4_suppl.010
Abstract #
10
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2013 Gastrointestinal Cancers Symposium
Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX).
Speaker: David Cunningham, MD FRCP
Videos & Slides
2011 ASCO Annual Meeting
Outcome and dose intensity (DI) in the elderly subgroup of the AGITG MAX phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic colorectal cancer (CRC).
Speaker: Timothy Jay Price, D.H.Sc, MBBS, FRACP
Speaker: Jonathan M. Marron, MD, MPH, FAAP
Speaker: Panel Discussion